New cancer drug enters first human trials for Tough-to-Treat tumors
NCT ID NCT05238883
Summary
This is an early-stage study to find a safe dose of a new immunotherapy drug called HFB200301. It is being tested alone and in combination with an existing drug (tislelizumab) in adults with advanced solid tumors who have already tried other treatments. The main goal is to see how well patients tolerate the drug and to determine the best dose for future studies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital Clinico Universitario de Valencia
Valencia, 46010, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Vall d'Hebron
Barcelona, 08035, Spain
-
Mayo Clinic
Scottsdale, Arizona, 85259, United States
-
Mayo Clinic
Jacksonville, Florida, 32224, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
NEXT Virginia Cancer Specialists
Fairfax, Virginia, 22031, United States
-
The University of Texas, MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
USC/Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.